Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials

dc.contributor
Institut Català de la Salut
dc.contributor
[Montobbio N, Bovis F, Signori A, Schiavetti I, Ponzano M] Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy. [Carmisciano L] Department of Clinical and Experimental Medicine, University of Pisa, Italy. [Tur C] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Montobbio, Noemi
dc.contributor.author
BOVIS, FRANCESCA
dc.contributor.author
Signori, Alessio
dc.contributor.author
Carmisciano, Luca
dc.contributor.author
Schiavetti, Irene
dc.contributor.author
Ponzano, Marta
dc.contributor.author
TUR, CARMEN
dc.date.accessioned
2025-10-24T07:36:16Z
dc.date.available
2025-10-24T07:36:16Z
dc.date.issued
2025-09-03T06:45:41Z
dc.date.issued
2025-09-03T06:45:41Z
dc.date.issued
2025-07
dc.identifier
Montobbio N, Bovis F, Signori A, Carmisciano L, Schiavetti I, Ponzano M, et al. Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials. eBioMedicine. 2025 Jul;117:105802.
dc.identifier
2352-3964
dc.identifier
http://hdl.handle.net/11351/13589
dc.identifier
10.1016/j.ebiom.2025.105802
dc.identifier
40554392
dc.identifier
001514390400002
dc.identifier.uri
http://hdl.handle.net/11351/13589
dc.description.abstract
Multiple sclerosis; Treatment effect bias; Progression independent of relapse activity (PIRA)
dc.description.abstract
Esclerosi múltiple; Biaix de l'efecte del tractament; Progressió independent de l'activitat de recaiguda
dc.description.abstract
Esclerosis múltiple; Sesgo del efecto del tratamiento; Progresión independiente de la actividad de recaída
dc.description.abstract
Background: Interest in progression independent of relapse activity (PIRA) as an endpoint in multiple sclerosis (MS) clinical trials is surging. However, established definitions of PIRA may produce biased treatment effect estimates in the presence of a treatment-induced relapse reduction. Methods: We applied different definitions of PIRA to pooled data from the OPERA I/II clinical trials (clinicaltrials.gov identifiers: NCT01247324, NCT01412333). Treatment effects on PIRA according to different methods were quantified by hazard ratios (HRs) and risk ratios (RRs). Next, we evaluated the bias in each definition using synthetic Expanded Disability Status Scale (EDSS) data simulating a control and an experimental arm with varying treatment effects on relapses and on PIRA. We quantified the bias by comparing the estimated effect on PIRA with the known true effect. Findings: The pooled OPERA I/II population included 1656 participants. Estimated treatment effects on PIRA varied from a non-significant HR of 0.83 (CI = 0.66-1.04) to an HR of 0.73 (CI = 0.59-0.90) depending on the definition used. Follow-up analyses on simulated data (n = 800 per arm) revealed an underestimation of the true treatment effect on PIRA when using established definitions, with increasing bias as treatment effect on relapses increased. Defining PIRA as complementary to relapse-associated worsening (RAW) provided a less biased and operationally simple alternative. Interpretation: For clinical trials with PIRA as an endpoint, we suggest a "complementary" definition of PIRA, relying on accurate exclusion of RAW promoted by appropriate visit timing.
dc.description.abstract
Italian Ministry of University and Research.
dc.format
application/pdf
dc.language
eng
dc.publisher
Elsevier
dc.relation
eBioMedicine;117
dc.relation
https://doi.org/10.1016/j.ebiom.2025.105802
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Scientia
dc.subject
Esclerosi múltiple - Tractament
dc.subject
Esclerosi múltiple - Prognosi
dc.subject
Esclerosi múltiple - Recaiguda
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence
dc.subject
DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression
dc.subject
HEALTH CARE::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Bias
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::recurrencia
dc.subject
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad
dc.subject
ATENCIÓN DE SALUD::calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::factores epidemiológicos::sesgo
dc.title
Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)